These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J, Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769 [Abstract] [Full Text] [Related]
52. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG. J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778 [Abstract] [Full Text] [Related]
57. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182 [Abstract] [Full Text] [Related]
58. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Cesne AL. Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966 [Abstract] [Full Text] [Related]